Education
About Us
Working with TipRanks
Follow Us
Brainstorm Cell Therapeutics (BCLI)
NASDAQ:BCLI
RESEARCH TOOLSreports
BCLI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.05 - $11.26
Previous CloseN/A
Volume34.73K
Average Volume (3M)30.93K
Market Cap
$8.21M
Enterprise Value$19.02M
Total Cash (Recent Filing)$942.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.43
Next Earnings
Mar 31, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.49
Shares Outstanding5,703,426
10 Day Avg. Volume34,536
30 Day Avg. Volume30,931
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market Cap2.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-71.76
Enterprise Value/Ebitda-1.42
Forecast
1Y Price Target
$10.00Price Target Upside594.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Brainstorm Cell Therapeutics News
PremiumCompany Announcements
Brainstorm Therapeutics Advances NurOwn® Phase 3b Trials---
Bulls Say, Bears Say
Bulls Say
Regulatory SupportChanges to the regulatory landscape seem to support a more favorable environment for NurOwn, with the agency more open to evaluating large datasets and understanding how biomarkers correlate with patient outcomes.
Study Success PotentialCombined with the special protocol assessment (SPA) agreement for NurOwn's P3b and alignment on manufacturing, there is an increasing probability of success for NurOwn provided the P3b data is positive.
Therapy ValidationThere is increasing traction for MSCs within ALS with 5 groups now targeting ALS, providing additional validation for NurOwn – BrainStorm's proprietary cell therapy platform.
Bears Say
Funding ConcernsA substantial amount of capital is expected to be needed to fund the program, which lowers the 12-month price target to $10, from a split-adjusted $30.
---
Ownership Overview
20.15% Insiders
2.23% Mutual Funds
2.66% Other Institutional Investors
74.10% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BCLI FAQ
What was Brainstorm Cell Therapeutics’s price range in the past 12 months?
Brainstorm Cell Therapeutics lowest stock price was $1.05 and its highest was $11.26 in the past 12 months.
What is Brainstorm Cell Therapeutics’s market cap?
Brainstorm Cell Therapeutics’s market cap is $8.21M.
When is Brainstorm Cell Therapeutics’s upcoming earnings report date?
Brainstorm Cell Therapeutics’s upcoming earnings report date is Mar 31, 2025 which is in 5 days.
How were Brainstorm Cell Therapeutics’s earnings last quarter?
Brainstorm Cell Therapeutics released its earnings results on Nov 14, 2024. The company reported -$0.51 earnings per share for the quarter, beating the consensus estimate of -$0.575 by $0.065.
Is Brainstorm Cell Therapeutics overvalued?
According to Wall Street analysts Brainstorm Cell Therapeutics’s price is currently Undervalued.
Does Brainstorm Cell Therapeutics pay dividends?
Brainstorm Cell Therapeutics does not currently pay dividends.
What is Brainstorm Cell Therapeutics’s EPS estimate?
Brainstorm Cell Therapeutics’s EPS estimate is -0.38.
How many shares outstanding does Brainstorm Cell Therapeutics have?
Brainstorm Cell Therapeutics has 5,703,426 shares outstanding.
What happened to Brainstorm Cell Therapeutics’s price movement after its last earnings report?
Brainstorm Cell Therapeutics reported an EPS of -$0.51 in its last earnings report, beating expectations of -$0.575. Following the earnings report the stock price went up 7.08%.
Which hedge fund is a major shareholder of Brainstorm Cell Therapeutics?
Currently, no hedge funds are holding shares in BCLI
---
Company Description
Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology company focused on developing innovative cellular therapies for neurodegenerative diseases. The company's core product, NurOwn, is an autologous stem cell-based treatment designed to promote repair and protection of neurons, showing promise in conditions such as Amyotrophic Lateral Sclerosis (ALS). Operating in the healthcare and biotechnology sectors, Brainstorm Cell Therapeutics aims to leverage its proprietary technology to address unmet medical needs in neurodegeneration.
---
BCLI Stock 12 Month Forecast
Average Price Target
$10.00
▲(594.44% Upside)
Technical Analysis
Best Analysts Covering BCLI
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-64.85%
reiterated a buy rating 3 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -64.85% per trade.
---